Biblio
Analysis of primary-refractory Hodgkin lymphoma pts in a randomized, placebo-controlled study of brentuximab vedotin consolidation after autologous stem cell transplant. Clin Adv Hematol Oncol. 2015;13 Suppl 9(8):14-15.
. Brentuximab Vedotin and Chemotherapy in Relapsed/Refractory Hodgkin Lymphoma: a Propensity Score Matched Analysis. Blood Adv. 2024.
Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy in relapsed/refractory classical Hodgkin lymphoma. Blood. 2023.
Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation. Haematologica. 2023.
Outcomes of Relapsed and Refractory Primary Mediastinal (Thymic) Large B-cell Lymphoma Treated with Second-line Therapy and Intent to Transplant. Biol Blood Marrow Transplant. 2018.
. .